Indivior is pioneering the development and discovery of non-opioid treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders.
Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients.
Indivior’s quarterly R&D and pipeline update can be found here.
Brand Name/Product Candidate
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory Approval
Commercial Launch
-
Treatment for Opioid Use Disorder
Buprenorphine Sublingual Tablet
-
Treatment for Opioid Use Disorder
Buprenorphine/Naloxone Sublingual Tablet
-
Treatment for Opioid Use Disorder
Buprenorphine/Naloxone Sublingual Film
-
Treatment for Opioid Use Disorder
RBP-6000 - Buprenorphine XR injection for Subcutaneous Use
-
Treatment for Schizophrenia
RBP-70001 - Risperidone XR injection for Subcutaneous Use
-
Treatment for Cannabis Use Disorder
AEF01172 - Cannabinoid-1 receptor synthetic Signaling Specific inhibitor (SSi)
-
Treatment for Substance Use Disorder
INDV-20003 - Selective Orexin-1 Receptor Antagonist
-
Treatment for Substance Use Disorder
INDV-10004 - Gamma-aminobutyric acid subtype B (GABA) positive allosteric modulator (PAM)
